AUTOLUS THERAPEUTICS PLC logo

AUTL

AUTOLUS THERAPEUTICS PLC

$2.64

Earnings Summary

Revenue
$0.29Mn
Net Profits
$-32.05Mn
Net Profit Margins
-10936.86%

Highlights

Revenue:

AUTOLUS THERAPEUTICS PLC’s revenue fell -13.31% since last year same period to $0.29Mn in the Q2 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated -13.31% fall in its revenue since last 3-months.

Net Profits:

AUTOLUS THERAPEUTICS PLC’s net profit fell -12.53% since last year same period to $-32.05Mn in the Q2 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated -7.27% fall in its net profits since last 3-months.

Net Profit Margins:

AUTOLUS THERAPEUTICS PLC’s net profit margin fell -29.81% since last year same period to -10936.86% in the Q2 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated -23.75% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AUTOLUS THERAPEUTICS PLC post its latest quarter earnings

EPS Estimate Current Quarter
-0.49
EPS Estimate Current Year
-0.49

Highlights

EPS Estimate Current Quarter:

AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a -3.97% fall from last quarter’s estimates.

EPS Estimate Current Year:

AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current year stand at -0.49.

Key Ratios

Key ratios of the AUTOLUS THERAPEUTICS PLC post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the AUTOLUS THERAPEUTICS PLC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-03-08
-0.49
0
100%
2022-03-31
-0.49
-0.41
16.82%

Company Information

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Organisation
AUTOLUS THERAPEUTICS PLC
Headquarters
The MediaWorks, London, United Kingdom, W12 7FP
Employees
324
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*